Navigation Links
Immunosyn Corporation Files 10-Q
Date:5/16/2008

LA JOLLA, Calif., May 16 /PRNewswire-FirstCall/ -- Immunosyn Corporation (OTC Bulletin Board: IMYN), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending March 31, 2008.

For the quarter ended March 31, 2008, the company incurred $175,632.00 in general and administrative expenses and $13,393.00 in interest expense which was funded from advances by affiliates of $179,798.00, accounts payable of $32,249.00 and accrued expenses of $12,151.00. As a result, the company had a Net Loss of $189,025.00 for the first quarter of 2008. During the same period in 2007, the company incurred $162,714.00 in general and administrative expenses and interest expense of $3,714.00 and had a Net Loss of $166,428.00. Immunosyn has had no revenue to date as Argyll Biotechnologies, LLC is still in the process of obtaining governmental and regulatory approval for SF-1019.

"We have continued to significantly control costs this quarter and appreciated the advances from affiliates," noted Stephen Ferrone, Immunosyn's CEO. "In 2008, Argyll Biotechnologies, LLC has reported positive research results for SF-1019 and Immunosyn hopes to add shareholder value by striving for financial efficiency in the execution of its marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC," added Ferrone.

Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. A limited proof of concept trial for SF-1019 in Europe has shown positive results in effectively treating diabetic ulcers. Immunosyn went public in January 2007 and its stock began trading on October 26, 2007 on the OTCBB under the symbol "IMYN."

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTC Bulletin Board: IMYN) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company's most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Immunosyn Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Immunosyn Corporation Announces 2007 Results, Files 10KSB
2. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
3. Immunosyn Announces Interview of CEO Stephen D. Ferrone by CEOCFO Interviews & News
4. WallSt.net Announces Upcoming Interview With CEO Of Immunosyn Corporation
5. Immunosyn Corporation Names G. David Criner as CFO
6. Immunosyn Corporation to Present at FSX
7. CorVel Corporation Announces Earnings Release Webcast
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
10. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... -- According to a new market research report "Oligonucleotide ... Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user ... global market is expected to reach USD 2.20 Billion by 2021 ... during the forecast period. Continue Reading ... ...
(Date:12/8/2016)... 2016 This report analyzes the worldwide markets for ... (Humic, Amino, & Fulvic), Extract Based, and Others. The report ... Ornamental & Turf, Row Crops, and Others. The report provides ... , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ...
(Date:12/8/2016)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ... today announced financial results for the fiscal first ... on our commitment to address an unmet medical ... pleased with the early clinical response data presented ... focused on advancing our lead program – ImmunoPulse® ...
(Date:12/8/2016)... AskLinkerReports.com has published a report on ... Industry 2016 Market Research Report. From a basic outline of ... are all covered in the report. This report projects investment ... of the Amyloglucosidase industry. ... , , Complete ...
Breaking Biology Technology:
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):